Study Population
This study will be conducted in patients with cutaneous or uveal melanoma at high risk of recurrence. Given the mechanism of action of tebentafusp, the study is limited to patients with the HLA-A*0201 subtype.
The patient population will be drawn from those completing adjuvant or local therapy for intermediate or high risk melanoma. Potential participants will be approached as they enter the last 3 months of adjuvant treatment for resected cutaneous melanoma, or within 9 months of completing such treatment. In the case of uveal melanoma, patients will be approached within 3 years of completing treatment for their primary tumour or oligometastatic disease.
